image header

News Releases

News Releases

Jun 14, 2021

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies Read more

Jun 10, 2021

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer Read more

May 18, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation Read more

May 17, 2021

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Read more

May 10, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma Read more

Apr 21, 2021

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer Read more

Apr 5, 2021

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148 Read more

Mar 18, 2021

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Read more

Mar 15, 2021

ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors Read more

Mar 4, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics Read more

Displaying 1 - 10 of 13